She has characterized the immune response to a range of viruses that cause morbidity and mortality in allogeneic hematopoietic stem cell transplant recipients and devised and clinically implemented immunotherapeutic strategies to treat patients with Adenovirus, BK virus, cytomegalovirus, Epstein Barr virus and Human Herpesvirus 6 infections. She serves as a principle investigator on numerous clinical trials performed under investigator-initiated Investigational New Drug (IND) applications and in 2013 was awarded an Outstanding New Investigator Award from the ASCGT for her work in developing novel cell therapies.